Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Merran MacPherson"'
Autor:
Michael Rademacher, Manuel Toledo, Wim Van Paesschen, Kore K. Liow, Ivan G. Milanov, Maria‐Luise Esch, Nan Wang, Merran MacPherson, William J. Byrnes, Timothy D. C. Minh, Elizabeth Webster, Konrad J. Werhahn
Publikováno v:
Epilepsia Open, Vol 7, Iss 4, Pp 758-770 (2022)
Abstract Objective To characterize efficacy, safety/tolerability, and pharmacokinetics of padsevonil (PSL) administered concomitantly with ≤3 antiseizure medications (ASMs) for observable focal seizures in adults with drug‐resistant epilepsy in t
Externí odkaz:
https://doaj.org/article/f7b64484d7ee4361b1b24f205981fd0f
Autor:
Shampa Das, Todd Riccobene, Timothy J. Carrothers, James G. Wright, Merran MacPherson, Andrew Cristinacce, Lynn McFadyen, Rujia Xie, Alison Luckey, Susan Raber
Purpose A series of iterative population pharmacokinetic (PK) modelling and probability of target attainment (PTA) analyses were undertaken to support dose optimization for aztreonam-avibactam, a combination antibiotic. Methods Joint PTA analyses (pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f44009c65371c38d29145c4cdcd0f535
https://doi.org/10.21203/rs.3.rs-2406580/v1
https://doi.org/10.21203/rs.3.rs-2406580/v1
Autor:
Joannellyn Chiu, Timothy J. Carrothers, James G. Wright, Jianguo Li, Yuan Xiong, Michelle Green, Shampa Das, Todd Riccobene, Craig Comisar, Jeremy Hing, Mark Lovern, Merran MacPherson, Diansong Zhou
Publikováno v:
CTS-CLINICAL AND TRANSLATIONAL SCIENCE
Clinical and Translational Science
Clinical and Translational Science
Ceftazidime‐avibactam is a novel β‐lactam/β‐lactamase inhibitor combination for the treatment of serious infections caused by resistant gram‐negative pathogens. Population pharmacokinetic (PopPK) models were built to incorporate pharmacokin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc190421b2815f160334ff112e93acf3
https://doi.org/10.1111/cts.12585
https://doi.org/10.1111/cts.12585
Autor:
Todd Riccobene, Shampa Das, Gregory G. Stone, Wright W. Nichols, Paul Newell, Katrina Yates, Angela Wardman, Helen Broadhurst, Merran MacPherson, Ian A. Critchley
Publikováno v:
Antimicrobial Agents and Chemotherapy
Clinical susceptibility breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa for the ceftazidime-avibactam dosage regimen of 2,000/500 mg every 8 h (q8h) by 2-h intravenous infusion (adjusted for renal function) have been established by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80c918415432eb2821ef2dc48fb2e787
Publikováno v:
Drugs in R&D
DRUGS IN R&D
DRUGS IN R&D
Objectives Our objective was to develop population pharmacokinetic (PK) models for ceftazidime and avibactam in the plasma and epithelial lining fluid (ELF) of healthy volunteers and to compare ELF concentrations to plasma PK/pharmacodynamic (PD) tar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::510b6e34d60eb69b336ff06265ec6a39
https://pubmed.ncbi.nlm.nih.gov/30054895
https://pubmed.ncbi.nlm.nih.gov/30054895
Publikováno v:
Diagnostic microbiology and infectious disease. 99(4)
For recently licensed antibiotics, such as the cephalosporin ceftaroline fosamil, probability of target attainment (PTA) curves, showing the percentage of patients reaching a predefined pharmacokinetic (PK)/pharmacodynamic (PD) target at different ba
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8b244dd0b1181ff15ae5f04402ab24e
https://pubmed.ncbi.nlm.nih.gov/33360809
https://pubmed.ncbi.nlm.nih.gov/33360809
Autor:
James Carmichael, Jeff White, Merran Macpherson, Mark Verrill, Alison Holt, Alan Swaisland, Chris Twelves, Jiri Horak, Mireille Cantarini, Adrian L. Harris, Helen Swaisland
PURPOSE: We investigated whether the pharmacokinetics and tolerability of gefitinib were altered in patients with hepatic impairment due to cirrhosis or hepatic metastases in two open, parallel-group, multicenter studies. METHODS: In Study 1, subject
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa4eacfc93bf5b534bc2de667716d41e
https://doi.org/10.1007/s00280-011-1611-2
https://doi.org/10.1007/s00280-011-1611-2
Autor:
Bengt Hamrén, Paul D. Martin, Marjet J. A. M. Braamskamp, Torbjörn Lundström, Merran Macpherson, John J. P. Kastelein
Publikováno v:
European journal of clinical pharmacology, 72(1), 19-27. Springer Verlag
Data from two clinical studies (hyperCholesterolaemia in cHildren and Adolescents taking Rosuvastatin OpeN label [CHARON; NCT01078675] and Study 4522IL/0086) were used to describe rosuvastatin pharmacokinetics in patients with heterozygous familial h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ed74bcdac2cfa3b892af6b5646d5eab
https://pure.amc.nl/en/publications/population-pharmacokinetics-of-rosuvastatin-in-pediatric-patients-with-heterozygous-familial-hypercholesterolemia(064e2cff-4e3d-4f4a-834a-931f862b6b11).html
https://pure.amc.nl/en/publications/population-pharmacokinetics-of-rosuvastatin-in-pediatric-patients-with-heterozygous-familial-hypercholesterolemia(064e2cff-4e3d-4f4a-834a-931f862b6b11).html
Autor:
Janusz Rolski, Patrick Neven, Kenjiro Fukase, Lawrence Panasci, Jose Chang, Justin P.O. Lindemann, Carmen Ianuli, Fatima Cardoso, Louis Mauriac, Merran Macpherson, Zsuzsanna Kahán, Kathleen I. Pritchard, Zsuzsanna Pápai
Publikováno v:
Breast Cancer Research and Treatment. 123:453-461
The Faslodex Investigation of Dose evaluation in Estrogen Receptor-positive advanced breast cancer (FINDER)2 study evaluated the efficacy, safety, and pharmacokinetics (PK) of three fulvestrant dosing regimens. FINDER2 enrolled Western postmenopausal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2946e0e78e6bde4a7e73ca65b37b6cf
https://doi.org/10.1007/s10549-010-1022-9
https://doi.org/10.1007/s10549-010-1022-9
Autor:
R Andrew Seaton, Emma Bell, Lindsay Semple, Elspeth Lamont, Alison H. Thomson, Merran Macpherson
Publikováno v:
Journal of Antimicrobial Chemotherapy. 64:181-187
The long elimination half-life of teicoplanin facilitates outpatient parenteral antibiotic therapy (OPAT) with thrice-weekly dosing. This study aimed to develop teicoplanin dosage guidelines for OPAT use from routine clinical data.Patients received 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e39c7e03084a2f249124c45c5a90941
https://doi.org/10.1093/jac/dkp147
https://doi.org/10.1093/jac/dkp147